148 related articles for article (PubMed ID: 31642953)
1. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease.
Yonguc T; Sefik E; Inci I; Kusbeci OY; Celik S; Aydın ME; Polat S
World J Urol; 2020 Aug; 38(8):2013-2019. PubMed ID: 31642953
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies.
Sand PK; Heesakkers J; Kraus SR; Carlsson M; Guan Z; Berriman S
Drugs Aging; 2012 Feb; 29(2):119-31. PubMed ID: 22276958
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial.
Wagg A; Khullar V; Michel MC; Oelke M; Darekar A; Bitoun CE
Neurourol Urodyn; 2014 Jan; 33(1):106-14. PubMed ID: 23460503
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
6. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
8. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
Grenabo L; Herschorn S; Kaplan SA; Cardozo L; Scholfield D; Arumi D; Carlsson M; Chapman D; Ntanios F
Curr Med Res Opin; 2017 Oct; 33(10):1731-1736. PubMed ID: 28758802
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
[TBL] [Abstract][Full Text] [Related]
12. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M
BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of fesoterodine over 24 hours in subjects with overactive bladder.
Staskin D; Michel MC; Nitti V; Morrow JD; Wang J; Guan Z
Curr Med Res Opin; 2010 Apr; 26(4):813-8. PubMed ID: 20121659
[TBL] [Abstract][Full Text] [Related]
14. Fesoterodine: a new agent for treating overactive bladder.
Ellsworth P; Berriman SJ; Brodsky M
Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of fesoterodine fumarate in patients with overactive bladder: results of a post-marketing surveillance study in Korea.
Kim TH; Lee SE; Lee HE; Lee KS
Curr Med Res Opin; 2016 Aug; 32(8):1361-6. PubMed ID: 27046653
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.
Kaplan SA; Cardozo L; Herschorn S; Grenabo L; Carlsson M; Arumi D; Crook TJ; Whelan L; Scholfield D; Ntanios F;
Int J Clin Pract; 2014 Sep; 68(9):1065-73. PubMed ID: 24898471
[TBL] [Abstract][Full Text] [Related]
17. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
Nitti VW; Rovner ES; Bavendam T
BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
[TBL] [Abstract][Full Text] [Related]
18. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.
Dubeau CE; Kraus SR; Griebling TL; Newman DK; Wyman JF; Johnson TM; Ouslander JG; Sun F; Gong J; Bavendam T
J Urol; 2014 Feb; 191(2):395-404. PubMed ID: 23973522
[TBL] [Abstract][Full Text] [Related]
19. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
[TBL] [Abstract][Full Text] [Related]
20. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
Staskin D; Khullar V; Michel MC; Morrow JD; Sun F; Guan Z; Dmochowski R
Neurourol Urodyn; 2011 Nov; 30(8):1480-5. PubMed ID: 21560158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]